Actively Recruiting
Shingrix In Recipients of Allogeneic Transplants
Led by University of Colorado, Denver · Updated on 2026-02-05
55
Participants Needed
1
Research Sites
370 weeks
Total Duration
On this page
Sponsors
U
University of Colorado, Denver
Lead Sponsor
G
GlaxoSmithKline
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval after transplantation on the immune response and if an additional dose of vaccine is needed to improve the vaccine-induced responses.
CONDITIONS
Official Title
Shingrix In Recipients of Allogeneic Transplants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 79 years at time of allogeneic stem cell transplant
- Written informed consent provided
- Received two doses of recombinant zoster vaccine (RZV), spaced 2 to 6 months apart, at least 1 year after transplant
- Enrollment at 18 months or more after second Shingrix dose
- Female participants of childbearing potential must use effective contraception for 30 days before vaccination, have a negative pregnancy test on vaccination days, and agree to continue contraception during vaccination and for 2 months after
- Investigator believes participant can comply with study requirements
You will not qualify if you...
- Active Graft Versus Host Disease at enrollment and before third RZV dose
- Use of 20 mg or more prednisone (or equivalent) daily for more than 2 weeks within 8 weeks before enrollment
- Receiving significant immunosuppressive therapy other than for graft maintenance as judged by investigator
- Received live vaccine within 4 weeks or inactivated vaccine within 2 weeks before enrollment
- History of herpes zoster after primary 2-dose RZV vaccination
- Pregnant or breastfeeding
- Receiving investigational drugs within 30 days before enrollment or planned during study
- Unable to comply with study schedule as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Colorado Hospital
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
T
Tori Rutherford, RN BSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here